Unum Therapeutics (NASDAQ:UMRX) Posts Earnings Results, Beats Estimates By $0.05 EPS

Share on StockTwits

Unum Therapeutics (NASDAQ:UMRX) issued its quarterly earnings data on Monday. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.05, Bloomberg Earnings reports. The firm had revenue of $3.14 million during the quarter, compared to analysts’ expectations of $3.10 million. Unum Therapeutics had a negative net margin of 373.81% and a negative return on equity of 62.24%.

Shares of UMRX stock opened at $1.91 on Wednesday. The stock has a 50-day moving average of $2.24. Unum Therapeutics has a 52 week low of $1.50 and a 52 week high of $16.72. The company has a current ratio of 2.65, a quick ratio of 2.65 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $55.12 million, a price-to-earnings ratio of -1.37 and a beta of 1.38.

A number of brokerages have recently issued reports on UMRX. Zacks Investment Research upgraded shares of Unum Therapeutics from a “hold” rating to a “buy” rating and set a $4.00 price objective for the company in a report on Friday, April 26th. HC Wainwright reiterated a “buy” rating on shares of Unum Therapeutics in a report on Tuesday. Wedbush reiterated an “outperform” rating and set a $13.00 price objective (down from $20.00) on shares of Unum Therapeutics in a report on Tuesday. They noted that the move was a valuation call. ValuEngine upgraded shares of Unum Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Finally, SunTrust Banks cut their price target on shares of Unum Therapeutics to $6.00 and set a “buy” rating on the stock in a report on Wednesday, July 3rd. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $12.40.

Several hedge funds and other institutional investors have recently bought and sold shares of UMRX. Acadian Asset Management LLC grew its stake in Unum Therapeutics by 134.8% during the second quarter. Acadian Asset Management LLC now owns 32,601 shares of the company’s stock valued at $85,000 after acquiring an additional 18,717 shares in the last quarter. Rhumbline Advisers purchased a new position in Unum Therapeutics during the first quarter valued at approximately $85,000. Bank of New York Mellon Corp grew its stake in Unum Therapeutics by 251.5% during the fourth quarter. Bank of New York Mellon Corp now owns 46,248 shares of the company’s stock valued at $204,000 after acquiring an additional 33,091 shares in the last quarter. D. E. Shaw & Co. Inc. grew its stake in Unum Therapeutics by 7.5% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 54,956 shares of the company’s stock valued at $242,000 after acquiring an additional 3,846 shares in the last quarter. Finally, Deutsche Bank AG grew its stake in Unum Therapeutics by 72.4% during the fourth quarter. Deutsche Bank AG now owns 63,657 shares of the company’s stock valued at $279,000 after acquiring an additional 26,742 shares in the last quarter. 47.16% of the stock is currently owned by institutional investors.

Unum Therapeutics Company Profile

Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL).

See Also: What is the downside to momentum investing?

Earnings History for Unum Therapeutics (NASDAQ:UMRX)

Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.